Virax Biolabs Group Ltd. (VRAX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
VRAX Chart
Why this biotech stock more than tripled on Thursday
Virax Biolabs (VRAX) shares exploded higher on Thursday morning after management announced a lucrative cross-border commercial breakthrough. In a press release dated July 9th, the company said its UK subsidiary signed an “exclusive” multi-country commercial supply agreement with Fosun Diagnostics, a key division of Shanghai Fosun Pharmaceutical.
Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why
Virax Biolabs Group Limited (VRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating
H.C. Wainwright initiated coverage on Virax Biolabs Group Limited VRAX, a U.K.-based company focused on detecting immune responses and diagnosing viral diseases.
Virax Biolabs Group Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 35,152.12 | $193,266.36 | $122,072.77 | -$71,193.59 | -36.84% |
 Christopher C. Powers Farther Finance Advisors, LLC | 0.84 | $13 | $3.18 | -$9.82 | -75.54% |
Virax Biolabs Group Ltd. (VRAX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Virax Biolabs Group Ltd. ever had a stock split?
Virax Biolabs Group Ltd. Profile
| Biotechnology Industry | Healthcare Sector | James Foster CEO | NASDAQ (CM) Exchange | G9495L133 CUSIP |
| GB Country | 26 Employees | - Last Dividend | 26 Jun 2026 Last Split | 21 Jul 2022 IPO Date |
Overview
Virax Biolabs Group Limited operates as a biotechnology company focused on offering a range of products designed for the prevention, detection, diagnosis, and risk management of viral diseases within the immunology field. With a product line encompassing diagnostics test kits and medical technologies, including personal protective equipment (PPE), the company caters to a wide audience that includes clinics, pharmacies, laboratories, hospitals, and even corporate environments. Beyond healthcare facilities, it also targets individual consumers, hospital systems, and public and private institutions across regions such as Europe, South America, the Asia Pacific, and Sub-Saharan Africa. Initially named Virax Biolabs (Cayman) Limited, the entity underwent a rebranding to Virax Biolabs Group Limited in September 2021 and is headquartered in London, United Kingdom. Founded in the same year, their offerings aim at addressing the demands of modern healthcare and occupational safety, reflecting a commitment to combating viral threats globally.
Products and Services
- Diagnostic Test Kits:
Virax Biolabs Group Limited provides an array of diagnostic tests under the ViraxClear brand, including rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction (PCR) rapid tests, and neutralizing antibody tests. These kits are essential for the timely and accurate detection of viral infections, catering to clinics, laboratories, and hospitals.
- Med-Tech and PPE Products:
The company markets a variety of med-tech and employee protection equipment products under the ViraxCare brand. The product line includes infrared thermometers, pulse oximeters, masks, gloves, and other PPE items. These products are crucial for preventing the spread of infections in both healthcare settings and the broader community.
- Nebulizing Machines and Smart Wearables:
In addition to diagnostic kits and PPE, Virax Biolabs distributes nebulizing machines and innovative smart wearable devices. These wearables are designed to alert employees and help them maintain social distancing guidelines, playing a critical role in mitigating viral transmission in corporate and public spaces.
- Online Platform:
The company operates an online platform for the sale of ViraxClear and ViraxCare products, facilitating easy access for customers ranging from individual consumers to large institutions. This platform ensures that a wide array of the company’s offerings are readily available to those in need, across various locations.
